The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.
Since President Donald Trump began his emphatic push to reduce drug prices, a looming question has been how low he could bring down the price
Plus, news about Cullinan, 4DMT, Axsome, AstraZeneca, Noema, UroGen Pharma, Halozyme and Benitec: ↩️ Dyne delays myotonic dystrophy plans again: Dyne said it now expects
Vera Therapeutics built its case for a rare kidney disease drug Thursday morning, revealing a fuller Phase 3 dataset after toplining the results earlier this
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. UPS has acquired US-based supply chain
Novo Nordisk has once again upped its bid for Metsera, according to sources familiar with the matter, in an effort to beat out a raised Pfizer offer that was delivered late Wednesday.
The exact details …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844